Protara TherapeuticsTARA
Market Cap: $40.6M
About: Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Employees: 27
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
73% more call options, than puts
Call options by funds: $52K | Put options by funds: $30K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
21% more capital invested
Capital invested by funds: $18.3M [Q1] → $22.2M (+$3.89M) [Q2]
12% more funds holding
Funds holding: 34 [Q1] → 38 (+4) [Q2]
10.76% more ownership
Funds ownership: 39.99% [Q1] → 50.75% (+10.76%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Oppenheimer Leland Gershell 64% 1-year accuracy 25 / 39 met price target | 1,169%upside $25 | Outperform Maintained | 12 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 73 / 162 met price target | 1,068%upside $23 | Buy Reiterated | 8 Aug 2024 |
Financial journalist opinion
Based on 3 articles about TARA published over the past 30 days